Karyopharm Therapeutics Inc. (KPTI) Dividend History

Karyopharm Therapeutics Inc. (KPTI) is a pharmaceutical company focused on the development and commercialization of novel therapies for cancer and other diseases. The company is known for its pioneering work in nuclear export inhibition, particularly through its lead product, selinexor, which is used to treat multiple myeloma and certain other hematologic cancers. Karyopharm’s approach involves targeting the nuclear export pathway to reactivate tumor suppressor proteins and enhance cancer cell death.

85 Wells Avenue, Newton, MA, 02459
Phone: 617-658-0600
Website: https://www.karyopharm.com

Dividend History

Karyopharm Therapeutics Inc. currently does not pay dividends

Company News

International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month

Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma, a blood cancer affecting over 176,404 people worldwide. This year, the International Myeloma Foundation invites individuals to share their most meaningful myeloma milestones, celebrating resilience, strengthening connections, and inspiring hope.

GlobeNewswire Inc.

Featured Companies: AMGN BMY GSKH JNJ REGN
Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033

The global glioblastoma multiforme treatment market is expected to grow from $2.78 billion in 2024 to $5.68 billion by 2033, driven by advancements in immunotherapy and research for better treatment options.

GlobeNewswire Inc.

Featured Companies: AMRX MRK PFE
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround

Karyopharm Therapeutics (KPTI) has been beaten down lately, but the stock is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier, indicating a potential turnaround.

Benzinga
Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire

The advanced melanoma therapeutics market is poised for significant growth, driven by the development of innovative biologics, particularly immunotherapy medications. The pipeline report highlights 55+ active players working on 60+ pipeline therapies for advanced melanoma treatment.

GlobeNewswire Inc.

Featured Companies: LYEL REPL
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript

KPTI earnings call for the period ending March 31, 2024.

The Motley Fool

Dividend data last updated 06/07/2025 20:27:54 UTC